Healthcare · NIFTY 500

Piramal Pharma Limited

NSEPPLPHARMA BSE543635 ISININE0DK501011 SeriesEQ Listed on NSE · BSE

₹245.07 -0.18 (-0.07%) Updated 12 Nov, 8:49 pm IST

Open chart Back to screener

Price, daily close+19.41% in a year

Today

Open: ₹245.78
Prev close: ₹245.25
Day high: ₹250.00
Day low: ₹243.84
Volume: 37.90 L
Value traded: ₹93.28 Cr
Upper circuit: ₹294.30
Lower circuit: ₹196.20
52W high: ₹245.07
52W low: ₹132.30
1 month: +21.83%
6 months: +29.96%

52W low52W high

Ratios

Key numbers

Worked out from the latest filings (Consolidated) and today's price. TTM = last four quarters.

Market cap₹32,555 Cr

P/E (TTM)—

P/B4.00

Book value / share₹61.29

EPS (TTM)₹-1.58

ROE-2.6%

Dividend yield—

Dividend (12m)—

Net margin (TTM)-2.1%

Operating margin13.3%

Debt / equity0.70

Current ratio1.41

EV / EBITDA38.31

Sales growth (YoY qtr)+28.05%

Profit growth (YoY qtr)+105.62%

Sales CAGR 3Y+7.79%

Profit CAGR 3Y—

Shares132.84 Cr

Quarterly results

Results for each quarter

Last 12 quarters, consolidated, ₹ crore. Hover a bar to see the number.

Revenue and net profit

1,95910.1

Dec 23

2,552101

Mar 24

1,951-88.6

Jun 24

2,24222.6

Sep 24

2,2043.7

Dec 24

2,754154

Mar 25

1,934-81.7

Jun 25

2,044-99.2

Sep 25

2,140-136

Dec 25

2,752-8.8

Mar 26

2,270-69.4

Jun 26

2,6175.6

Sep 26

Revenue · QoQ (vs last quarter)

—+30%-24%+15%-1.7%+25%-30%+5.7%+4.7%+29%-18%+15%

Revenue · YoY (vs a year ago)

————+13%+7.9%-0.9%-8.8%-2.9%-0.1%+17%+28%

Net profit · QoQ (vs last quarter)

—+902%-188%+125%-84%+4,071%-153%-21%-37%+94%-687%+108%

Net profit · YoY (vs a year ago)

————-64%+52%+7.8%-539%-3,801%-106%+15%+106%

RevenueNet profitLine = trend

0.08

Dec 23

0.77

Mar 24

-0.67

Jun 24

0.17

Sep 24

0.03

Dec 24

1.16

Mar 25

-0.62

Jun 25

-0.75

Sep 25

-1.03

Dec 25

-0.07

Mar 26

-0.52

Jun 26

0.04

Sep 26

EPS (₹) · YoY (vs a year ago)

————-63%+51%+7.5%-541%-3,533%-106%+16%+105%

EPS (₹)Line = trend

₹ Cr	Dec 23	Mar 24	Jun 24	Sep 24	Dec 24	Mar 25	Jun 25	Sep 25	Dec 25	Mar 26	Jun 26	Sep 26
Revenue	1,959	2,552	1,951	2,242	2,204	2,754	1,934	2,044	2,140	2,752	2,270	2,617
Other income	61.5	26.4	19.5	61.1	12.1	42.0	58.4	65.6	43.2	46.1	89.4	35.9
Total income	2,020	2,579	1,971	2,303	2,216	2,796	1,992	2,109	2,183	2,798	2,359	2,653
Raw material	628	400	471	575	805	204	524	483	505	483	725	646
Purchases	228	436	315	395	161	547	343	375	377	336	420	335
Employee cost	524	494	580	560	556	612	619	611	600	586	676	714
Other expenses	491	514	493	544	504	626	514	571	558	650	547	648
Total expenses	1,982	2,333	2,038	2,200	2,167	2,540	2,110	2,170	2,246	2,593	2,386	2,589
Operating profit	236	499	204	342	338	561	127	159	155	285	195	349
OPM %	12.1%	19.6%	10.5%	15.2%	15.3%	20.4%	6.6%	7.8%	7.2%	10.3%	8.6%	13.3%
Finance cost	106	114	107	108	103	104	86.2	82.4	89.2	83.0	88.1	87.6
Depreciation	186	196	185	192	197	243	197	203	213	218	224	233
Exceptional items	-32.3	-30.5	—	—	—	—	20.7	—	-41.1	-176	—	—
Profit before tax	5.4	215	-67.5	103	49.8	257	-97.6	-61.0	-104	29.4	-27.0	63.9
Tax	9.3	126	43.6	97.5	63.1	119	2.7	53.0	42.3	51.8	61.9	76.6
Net profit	10.1	101	-88.6	22.6	3.7	154	-81.7	-99.2	-136	-8.8	-69.4	5.0
Profit to shareholders	—	—	-88.6	22.6	3.7	154	-81.7	-99.2	-136	-8.8	-69.4	5.6
EPS (₹)	0.08	0.77	-0.67	0.17	0.03	1.16	-0.62	-0.75	-1.03	-0.07	-0.52	0.04

Profit & loss

Results for each year

4 financial years (April to March), consolidated, ₹ crore.

Sales, operating profit and net profit

7,082621-186

FY23

8,1711,13317.8

FY24

9,1511,44591.1

FY25

8,869725-326

FY26

Revenue · YoY (vs a year ago)

—+15%+12%-3.1%

Net profit · YoY (vs a year ago)

—+110%+411%-458%

RevenueOperating profitNet profitLine = trend

₹ Cr	FY23	FY24	FY25	FY26
Revenue	7,082	8,171	9,151	8,869
Other income	225	175	135	213
Total expenses	7,474	8,164	8,944	9,120
Employee cost	1,896	2,030	2,307	2,416
Operating profit	621	1,133	1,445	725
OPM %	8.8%	13.9%	15.8%	8.2%
Finance cost	344	448	422	341
Depreciation	677	741	816	831
Profit before tax	-174	120	342	-233
Tax	66.3	161	324	150
Tax rate %	—	134.8%	94.7%	—
Net profit	-186	17.8	91.1	-326
Profit to shareholders	—	—	91.1	-326
Net margin %	-2.6%	0.2%	1.0%	-3.7%
EPS (₹)	-1.57	0.14	0.68	-2.46

Balance sheet

Assets and debt

At each year end (and the latest half year), ₹ crore.

Equity, debt and assets

6,7745,505196

Mar 23

7,9114,559357

Mar 24

8,1254,720369

Mar 25

8,1635,4951,200

Mar 26

8,1425,665545

Sep 26

Shareholders' equity · YoY (vs a year ago)

—+17%+2.7%+0.5%—

Shareholders' equityBorrowingsCashLine = trend

₹ Cr	Mar 23	Mar 24	Mar 25	Mar 26	Sep 26
Shareholders' equity	6,774	7,911	8,125	8,163	8,142
Long-term borrowings	3,384	2,484	3,214	4,300	4,454
Short-term borrowings	2,121	2,075	1,506	1,196	1,212
Total borrowings	5,505	4,559	4,720	5,495	5,665
Current liabilities	3,843	4,369	3,766	4,758	5,159
Fixed assets (PPE)	3,363	3,873	4,176	4,451	4,496
Inventories	1,681	2,176	2,313	3,064	3,295
Trade receivables	1,799	2,134	2,350	2,158	2,254
Cash & equivalents	196	357	369	1,200	545
Current assets	4,835	5,464	5,797	7,192	7,254
Total assets	14,523	15,312	15,678	17,965	18,537
Debt / equity	0.81	0.58	0.58	0.67	0.70

Cash flow

Cash coming in and going out

For each financial year, ₹ crore. Free cash flow = cash from operations minus spending on fixed assets.

Operating, investing and financing cash

484-1,339818

FY23

1,005-434-422

FY24

892-477-441

FY25

1,653-826-39.0

FY26

Operations · YoY (vs a year ago)

—+108%-11%+85%

OperationsInvestingFinancingLine = trend

₹ Cr	FY23	FY24	FY25	FY26
Cash from operations	484	1,005	892	1,653
Cash from investing	-1,339	-434	-477	-826
Cash from financing	818	-422	-441	-39.0
Spent on fixed assets	-965	-712	-664	-890
Free cash flow	-481	293	228	763
Net cash flow	-37.1	148	-26.0	788

Shareholding

Who holds the shares

Promoter and public holding at each quarter end, as filed with NSE.

Holding over time

35.0%Dec 23

35.0%Mar 24

35.0%Jun 24

35.0%Sep 24

35.0%Dec 24

35.0%Mar 25

34.9%Jun 25

34.9%Sep 25

34.9%Dec 25

34.9%Mar 26

34.8%Jun 26

34.8%Sep 26

Promoter & groupPublic

Latest (30 Sep 2026)

34.8%promoter

Promoter & group: 34.80%
Public (FIIs, mutual funds, retail…): 64.80%
Employee trusts: 0.40%
Promoter change, last quarter: 0.00 pts

Dividends & news

Latest dividends and announcements

Dividends & corporate actions

Dividend - Re 0.14 Per ShareEx 16-Jul-2025
Dividend - Rs 0.11 Per ShareEx 12-Jul-2024
Rights 5:46 @ Premium Rs 71/-Ex 02-Aug-2023

Board meetings

Piramal Pharma Limited has informed the Exchange about Board Meeting to be held on 27-Oct-2026 to inter-alia consider and approve the Unaudited Finan…27-Oct-2026
the financial results for the period ended September 30, 202627-Oct-2026
the financial results for the period ended Jun 30, 202629-Jul-2026
Piramal Pharma Limited has informed the Exchange about Board Meeting to be held on 29-Jul-2026 to inter-alia consider and approve the Unaudited Finan…29-Jul-2026
the Audited Financial Results (Standalone and Consolidated) of the Company for quarter and financial year ended 31st March, 2026.28-Apr-2026

Filings with NSE

Analysts/Institutional Investor Meet/Con. Call Updates30 Oct
Analysts/Institutional Investor Meet/Con. Call Updates30 Oct
Analysts/Institutional Investor Meet/Con. Call Updates28 Oct
Analysts/Institutional Investor Meet/Con. Call Updates27 Oct
Investor Presentation27 Oct
Press Release27 Oct
Outcome of Board Meeting27 Oct

Latest news

Piramal Pharma soars 15% in weak market on huge volume post Q2 resultsBusiness Standard · 28 Oct, 12:30 pm Piramal Pharma Shares Surge 14% After Q2 FY27 Results, Raises FY27 Growth OutlookIndia Infoline · 28 Oct, 12:30 pm Piramal Pharma surges 18% to 18-month high as Q2 results beat estimates; brokerage upgrades to Add, check...Moneycontrol.com · 28 Oct, 12:30 pm Piramal Pharma shares rally 15% as firm swings to profit in Q2; upgrades FY27 outlookUpstox · 27 Oct, 12:30 pm Piramal Pharma Share Price Spikes Over 10% — What Is Driving The Rally?NDTV Profit · 23 Jun, 12:30 pm Piramal Pharma Share Price Today Down 2.44%: What It ShowsUnivest · 21 Oct, 12:30 pm Piramal Pharma shares: Expert sees Rs 238 target after breakout; should you sell on rally?Business Today · 31 Jul, 12:30 pm Piramal Pharma shares rise 4% on successful closure of US FDA inspectionBusiness Standard · 9 Jul, 12:30 pm

About

About Piramal Pharma Limited

Piramal Group is an Indian multinational conglomerate headquartered in Mumbai, with operations in financial services, pharmaceuticals, and real estate. Ajay Piramal established the group in 1984 through the acquisition of Gujarat Glass Limited; the family had previously been in textiles. In 1988 the group entered healthcare through the purchase of Nicholas Laboratories' Indian operations.

From Wikipedia (CC BY-SA 4.0).

Company details

Company name: Piramal Pharma Limited
NSE symbol: PPLPHARMA
BSE scrip code: 543635
ISIN: INE0DK501011
Listed on: NSE, BSE
Series: EQ (normal equity)
Listed on NSE since: 19 Oct 2022
Face value: ₹10 per share
Market lot: 1 share
Shares issued: 132.84 crore
Index: NIFTY 500
Sector (NSE): Healthcare
Industry: Pharmaceuticals: Major
Managing director / CEO: Peter DeYoung
Chair: Nandini Piramal
Headquarters: Mumbai, IN
Founded: 2020
Employees: 10,440
Financial year: April to March
Results basis: Consolidated
Website: piramalpharma.com

Peers

Other Healthcare stocks

Prices from NSE via Upstox. Financials from the company's results filed with NSE (XBRL); ratios are our own working. Profile from global-stock-logos (MIT). For information only, not a recommendation to buy or sell.

India, Wall Street, crypto and commodities, live.

Every product, one clear workflow.

Built from data, on the record.

A clearer view of the markets.

Calculators and tools that show the maths.

Read the numbers, not the noise.

Piramal Pharma Limited

Today

Ratios

Quarterly results

Revenue and net profit

Profit & loss

Sales, operating profit and net profit

Balance sheet

Equity, debt and assets

Cash flow

Operating, investing and financing cash

Shareholding

Holding over time

Latest (30 Sep 2026)

Dividends & news

Dividends & corporate actions

Board meetings

Filings with NSE

Latest news

About

Company details

Peers